ClinicalTrials.gg
CompletedNCT07514741GRASPUpdated Oct 14, 2026

Safety and Efficacy of a Prebiotic Blend in Healthy Humans

An interventional study of Fiber Blend 1 (Low Dose) and Fiber Blend 2 (High Dose) in Healthy Adult Participants, sponsored by LOAM Science. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by LOAM Science · Not applicable, Interventional, and Prevention

How we know

Updated Oct 14, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The GRASP Trial is a 30-day, randomized, double-blind, placebo-controlled study (Protocol No.: GW-2025-02) designed to evaluate the safety and tolerability of a novel multi-fiber prebiotic blend in healthy adult volunteers (age 18-60, normal BMI). Participants will be randomized (1:1:1) to receive either a low dose (1 dose/day), a high dose (2 doses/day), or an identical placebo powder for 30 days. The primary objective is to evaluate safety and tolerability, measured by the incidence and severity of gastrointestinal adverse events (AEs) and discontinuations. Secondary objectives include assessing the fiber blend's impact on gastrointestinal symptoms (measured by the Gastrointestinal Symptom Rating Scale or GSRS score), beneficial gut microbiome composition (specifically SCFA-producing bacteria like Bifidobacterium spp.), and gut barrier function/inflammation (via markers like LBP, zonulin, hs-CRP, and IL-6). Exploratory objectives will examine effects on sleep and activity patterns using a wearable tracker, as well as quality of life (SF-36) and stress (PSS). The trial includes assessments at baseline (Day 0) and end-of-treatment (Day 28 ± 2), including the collection of blood, urine, and stool samples for comprehensive analysis.

Read the detailed description

The GRASP Trial (protocol GW-2025-02) is a randomized, double-blind, placebo-controlled clinical study sponsored by GutWise Inc. (dba LOAM Science). The trial investigates the effects of a multi-fiber prebiotic blend on gastrointestinal comfort, gut microbiome composition, and markers of systemic well-being in healthy adults.

The study follows Good Clinical Practice (GCP) and includes approximately 90 participants allocated equally to three parallel arms: one-dose Fiber Blend, two-dose Fiber Blend, or placebo. Each participant completes a 2-week run-in period followed by a 30-day intervention. The investigational product is a powdered prebiotic formulation containing six well-characterized soluble fibers-Partially Hydrolyzed Guar Gum, Rhamnogalacturonan-I (from carrot), Xylo-oligosaccharides, Resistant Maltodextrin, Tapioca Soluble Fiber, and Wheat Dextrin. The placebo is a visually and organoleptically matched inert powder to ensure blinding integrity.

Participants are healthy men and women aged 18-60 years with normal BMI and no active gastrointestinal disease. Eligible individuals maintain their regular diet and lifestyle and use a wearable tracker to record sleep and activity during the trial.

The study primarily evaluates safety and tolerability, with daily symptom monitoring and predefined adverse-event grading. Secondary and exploratory analyses examine gastrointestinal symptom changes (GSRS), gut microbiota profiles, systemic biomarkers of gut-barrier integrity and inflammation, and quality-of-life and stress metrics (SF-36 and PSS). Objective digital health endpoints (sleep, heart rate, steps) complement biochemical and microbiome measures to explore broader physiological effects of dietary fiber supplementation.

Clinical visits occur at screening, baseline, midpoint, and end of treatment, followed by a brief safety follow-up. Biological samples (blood, urine, stool) are collected at baseline and day 30 for analysis of microbial composition and metabolites, including short-chain fatty acids. Data are captured via secure electronic diaries and the Chloe data platform, ensuring regulatory-grade privacy compliance and data traceability.

Overall, this study aims to characterize how compositional diversity and dosing of a multi-fiber blend influence gastrointestinal comfort, gut microbiome dynamics, and systemic metabolic and neuro-gut signaling markers in healthy adults.

02

Conditions studied

  • Healthy Adult Participants

Keywords

  • microbiome
  • prebiotic
  • health
03

In context

Lead sponsor

LOAM Science is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged 18 to 60 years.
  • (BMI) in the normal range (approximately 18.5-24.9 kg/m²).
  • Generally healthy with no active chronic illnesses.
  • No significant gastrointestinal disorders (e.g., no diagnosis of irritable bowel syndrome, inflammatory bowel disease, celiac disease, or similar conditions).
  • No history of other chronic diseases such as hypertension, hypercholesterolemia, diabetes, or comparable conditions.
  • If female, not pregnant or lactating.
  • Women of must have a negative pregnancy test at screening and agree to use during the study.
  • Willing to maintain their usual diet and lifestyle during the trial.
  • Willing to refrain from starting any new supplements or probiotics during the study.
  • Willing to consume the study product daily as directed.
  • Owns a personal wearable fitness tracker (such as Fitbit or similar) that can be used for the duration of the study.
  • Able to provide .
  • Able and willing to comply with all study procedures (including questionnaires, sample collection, and wearing the activity tracker).

Exclusion criteria

Exclusion Criteria:

  • Any history of significant gastrointestinal disease or surgery (e.g., inflammatory bowel disease, malabsorption syndromes, or gastrointestinal surgery affecting digestion or absorption) that could confound results or pose risks.
  • Use of antibiotics or probiotic/prebiotic supplements in the last 4 weeks.
  • Presence of chronic medical conditions such as uncontrolled diabetes, severe allergies, diseases, or any condition requiring therapy.
  • Pregnant or breastfeeding.
  • Known allergy or intolerance to fiber supplements or any ingredients in the product (e.g., severe wheat allergy or gluten sensitivity related to wheat dextrin content).
  • Abnormal screening laboratory values or clinical findings that, in the investigator's opinion, make participation unsafe (e.g., significantly abnormal liver or kidney function tests, anemia).
  • Active psychiatric disorders or use of medications that could significantly affect gastrointestinal motility (e.g., chronic opioid therapy) or mood (e.g., certain antidepressants), if these are judged likely to interfere with participation or outcomes.
  • Current smoking, heavy smoking, or other tobacco use, if exclusion of smokers is desired to maintain a healthy cohort.
  • Excessive alcohol consumption or illicit drug use that may interfere with safety or adherence.
  • Participation in another clinical trial of an investigational product or device within the past 30 days.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    One daily dose of an identical-looking, non-active powder.

    Other: Placebo

  • Active comparator
    Arm 1: Fiber Blend 1 (Low Dose)

    One daily dose of the prebiotic fiber blend.

    Dietary Supplement: Fiber Blend 1 (Low Dose)

  • Active comparator
    Arm 2: Fiber Blend 2 (High Dose)

    Two daily doses of the prebiotic fiber blend.

    Dietary Supplement: Fiber Blend 2 (High Dose)

Interventions

  • Dietary supplementFiber Blend 1 (Low Dose)

    One daily dose of the prebiotic fiber blend.

  • Dietary supplementFiber Blend 2 (High Dose)

    Two daily doses of the prebiotic fiber blend.

  • OtherPlacebo

    One daily dose of an identical-looking, non-active powder.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of GI adverse events (AEs) and discontinuations.

    To evaluate the safety and tolerability of the fiber blend.

    Time frame: 0, 1, 2, 3, 4 weeks

Secondary outcomes

  1. Change in the Gastrointestinal Symptom Rating Scale (GSRS) total score

    The Gastrointestinal Symptom Rating Scale (GSRS) is a validated patient-reported questionnaire assessing gastrointestinal symptoms across 15 items grouped into five domains (abdominal pain, reflux, indigestion, diarrhea, and constipation). Each item is rated on a 7-point Likert scale, where 1 = no discomfort and 7 = very severe discomfort. The total GSRS score ranges from 15 to 105, with higher scores indicating worse gastrointestinal symptoms (poorer outcome).

    Time frame: Baseline (Week 0), Week 2, Week 4

  2. Gut Microbiome Composition

    Changes in alpha diversity and relative abundance of SCFA-producing bacteria (e.g., Faecalibacterium prausnitzii, Bifidobacterium spp.).

    Time frame: 0 and 4 weeks

  3. Gut Barrier Function and Inflammation

    Changes in serum markers including lipopolysaccharide-binding protein (LBP), zonulin, hs-CRP, and IL-6.

    Time frame: 0 and 4 weeks

  4. Metabolic and Neurotransmitter Markers

    Fecal short-chain fatty acids (SCFAs) (butyrate, acetate, propionate) and Plasma or urine GABA.

    Time frame: 0 and 4 weeks

Other outcomes

  1. Total Sleep Time

    Total sleep time (minutes per night) measured by a validated wearable tracker. Higher values indicate longer sleep duration (better outcome).

    Time frame: Continuous measurement throughout the 30 days; data downloaded at Day 30

  2. Quality of Life (SF-36 Total Score)

    The 36-Item Short Form Health Survey (SF-36) is a validated questionnaire assessing eight domains of health-related quality of life, including physical functioning, bodily pain, general health, vitality, social functioning, and mental health. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life (better outcome).

    Time frame: Baseline (Week 0), Week 2, and Week 4

  3. Bristol Stool Form Scale

    Daily stool type (1-7) to assess stool normalization/GI motility.

    Time frame: Daily tracking throughout the intervention (Days 1-30).

  4. Perceived Stress (PSS Total Score)

    The Perceived Stress Scale (PSS) is a 10-item self-report questionnaire that measures the degree to which situations in one's life are appraised as stressful. Each item is rated on a 5-point Likert scale (0 = never to 4 = very often), yielding a total score from 0 to 40, with higher scores indicating greater perceived stress (worse outcome).

    Time frame: Baseline (Week 0), Week 2, and Week 4

  5. Sleep Efficiency

    Sleep efficiency calculated as the ratio of total sleep time to time in bed, expressed as a percentage (%). Higher percentages indicate better sleep quality (better outcome).

    Time frame: Continuous measurement throughout the 30 days; data downloaded at Day 30

  6. Resting Heart Rate

    Mean resting heart rate (beats per minute) measured by a validated wearable device. Lower values indicate better cardiovascular fitness (better outcome).

    Time frame: Continuous measurement throughout the 30 days; data downloaded at Day 30

  7. Daily Step Count

    Mean daily step count (steps per day) measured by a wearable tracker. Higher values indicate higher physical activity (better outcome).

    Time frame: Continuous measurement throughout the 30 days; data downloaded at Day 30

07

Study locations

1 site
  • Next Health
    West Hollywood, California 90069, United States
08

References and documents

Individual participant data

Plan to share: No — The data is propriatery data

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2026 to primary completion in Aug 2026, 3 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2026 → Aug 2026 and completion Apr 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Apr 7, 2026
StartActual
Apr 25, 2026
Primary completionActual
Aug 19, 2026was Apr 2026
CompletionActual
Aug 19, 2026was Apr 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 14, 2026
Primary completion
Apr 25, 2026→Aug 19, 2026 (actual)
Oct 14, 2026
Study completion
Apr 25, 2026→Aug 19, 2026 (actual)
Oct 14, 2026
Enrollment
90 (estimated)→87 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Enrolling by invitation→Completed
    Primary completion Apr 25, 2026→Aug 19, 2026 (now actual)
    Study completion Apr 25, 2026→Aug 19, 2026 (now actual)
    Enrollment 90 (estimated)→87 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07514741
Lead sponsor
LOAM Science
Collaborators
People Science, Inc.
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Apr 25, 2026
Primary completion
Aug 19, 2026
Completion
Aug 19, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion